Question 1

What evidence establishes astrocyte identity?

Accepted Answer

Marker staining is a starting point, not a conclusion, since several markers are shared with neural progenitors and one common marker tracks reactivity rather than identity. Transcriptome correlation with primary human astrocytes, together with at least one astrocyte-specific function such as glutamate clearance, forms the accepted standard.

Question 2

Why do derived astrocytes remain immature, and what helps?

Accepted Answer

Human astrocyte maturation occupies years in development, which no culture protocol reproduces. Extended culture, co-culture with neurons, three-dimensional organoid formats and defined maturation factors each shift cells partway. Reporting a maturity assessment against primary reference data, rather than asserting maturity, is what distinguishes careful work here.

Question 3

How is reactivity distinguished from disease phenotype?

Accepted Answer

Culture stress, serum exposure, passaging and dissociation all induce a reactive profile that overlaps substantially with signatures reported in disease. Characterising baseline reactivity in every line before treatment, and matching handling exactly across conditions, prevents a common artefact from being reported as patient-specific biology.

Question 4

Which functional assays are most informative?

Accepted Answer

Glutamate uptake capacity, potassium buffering measured electrophysiologically, calcium responses to neurotransmitter stimulation, and the ability to support synapse formation and neuronal survival in co-culture. Each probes a distinct astrocyte role, and reporting two or three gives a much stronger identity claim than any marker panel.

Question 5

Does regional identity need to be specified?

Accepted Answer

Astrocytes differ substantially between spinal cord, cortex and midbrain in gene expression and function, and disease relevance is region-dependent. Protocols patterned toward the region affected in the modelled condition give more interpretable results, and the patterning strategy and its verification should be reported explicitly.

Question 6

What controls belong in patient-derived comparisons?

Accepted Answer

Line-to-line variability between individuals frequently exceeds the disease effect. Isogenic pairs created by correcting or introducing the variant provide the strongest control, and where that is not feasible, several independent patient and control lines analysed as biological replicates are the minimum. Clone-level variation should also be assessed.

Biotechnology

Biotechnology

Research Frontiers in Astrocyte Differentiation Programming